

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of: Browning et al.

Examiner: A. Holleran

Serial No.: 09/626,219

Group Art Unit: 1642

Filing Date: July 26, 2000

For: TREATMENT OF FOLLICULAR LYMPHOMAS USING INHIBITORS
OF THE LT PATHWAY

Certificate of Mailing by First Class Mail

I hereby certify that this correspondence is being mailed via United States First Class Mail to: Assistant Commissioner
for Patents, Washington, D.C. 20231.

10/31/01
Date

Jeanne Schmitter
Jeanne Schmitter

RESPONSE TO RESTRICTION REQUIREMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

In response to the restriction requirement mailed on October 2, 2001, Applicants hereby elect to prosecute the claims of Group I (claims 1-10, 12-17), species v (soluble LT beta receptor). Applicants expressly reserve the right to prosecute and obtain allowance of claims directed to the species of Groups II and III in divisional applications filed during the pendency of the present application.

Concurrently filed herewith is a preliminary amendment.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to Deposit Account No. 02-2327. However,

RECEIVED

JAN 09 2002

TECH CENTER 1600/2900

#5
Jm
1/10/02




the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

If the Examiner believes that a telephone conference would expedite the prosecution of this application, please call the undersigned at (617)-679-2079.

Respectfully submitted,

Date: 10-31-01



Niki D. Cox, Esq.
Reg. No. 42, 446

BIOGEN, INC.
14 Cambridge Center
Cambridge, MA 02142
(617) 679-2079 (Direct)
(617) 679-2838 (Facsimile)